サマリー

The global antifungal drugs market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 4% during 2021-2026.

Antifungal drugs, or antimycotic drugs, refer to the pharmaceutical medicines used for the treatment of fungal infections on skin, hair and nails. Some of the commonly used antifungal drugs include polyenes, azoles and allylamines. They specifically neutralize fungal agents and dermatophytes, such as candida and tapeworms, and aid in the treatment of athlete’s foot, ringworm, aspergillosis, candidiasis and fungal meningitis. These drugs are commonly available in over the counter (OTC) capsule, gel, liquid and pill variants or intravenous solutions that are injected directly into the bloodstream to minimize and prevent fungal infection.

Antifungal Drugs Market Trends:
The increasing prevalence of fungal and nosocomial infections is one of the key factors creating a positive outlook for the market growth. Antifungal drugs are effective against both systemic and superficial infections that are acquired from exposure to contaminated surfaces in hospitals or humid conditions. Moreover, the convenient availability of OTC drugs in both urban and rural areas is providing a thrust to the market growth. With the rising health consciousness among the masses, consumers are increasingly opting for OTC therapeutics to timely treat minor infections. Additionally, various product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, are acting as other growth-inducing factors. Pharmaceutical manufacturers are also investing extensively in the research and development (R&D) of novel therapeutics in the form of sprays, creams, tablets and injections with enhanced efficacy. Other factors, including significant growth in the pharmaceutical industry, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antifungal drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, drug class and indication.

Breakup by Drug Class:

Azoles
Voriconazole (Vfend)
Posaconazole (Noxafil)
Clotrimazole (Canesten)
Isavuconazole (CRESEMBA)
Others
Echinocandins
Caspofungin (Cancidas)
Micafungin (Mycamine/ Funguard)
Others
Polyenes
Amphotericin (AmBisome)
Others
Allylamines
Terbinafine (Lamisil)
Others
Others

Breakup by Indication:

Dermatophytosis
Aspergillosis
Candidiasis
Invasive Candidiasis
Vulvovaginal Candidiasis (VVC)
Mouth/Throat/Esophageal Candidiasis
Others
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc., Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Scynexis Inc. Key Questions Answered in This Report:
How has the global antifungal drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global antifungal drugs market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the indication?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global antifungal drugs market and who are the key players?
What is the degree of competition in the industry?

ページTOPに戻る

目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Antifungal Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Azoles
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Voriconazole (Vfend)
6.1.2.2 Posaconazole (Noxafil)
6.1.2.3 Clotrimazole (Canesten)
6.1.2.4 Isavuconazole (CRESEMBA)
6.1.2.5 Others
6.1.3 Market Forecast
6.2 Echinocandins
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Caspofungin (Cancidas)
6.2.2.2 Micafungin (Mycamine/ Funguard)
6.2.2.3 Others
6.2.3 Market Forecast
6.3 Polyenes
6.3.1 Market Trends
6.3.2 Key Segments
6.3.2.1 Amphotericin (AmBisome)
6.3.2.2 Others
6.3.3 Market Forecast
6.4 Allylamines
6.4.1 Market Trends
6.4.2 Key Segments
6.4.2.1 Terbinafine (Lamisil)
6.4.2.2 Others
6.4.3 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Indication
7.1 Dermatophytosis
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Aspergillosis
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Candidiasis
7.3.1 Market Trends
7.3.2 Key Segments
7.3.2.1 Invasive Candidiasis
7.3.2.2 Vulvovaginal Candidiasis (VVC)
7.3.2.3 Mouth/Throat/Esophageal Candidiasis
7.3.2.4 Others
7.3.3 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia-Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 Abbott Laboratories
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.1.4 SWOT Analysis
13.3.2 Arcadia Consumer Healthcare Inc.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.3 Astellas Pharma Inc.
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.3.4 SWOT Analysis
13.3.4 Bayer AG
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 GlaxoSmithKline Plc
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.6 Merck & Co. Inc.
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 Financials
13.3.6.4 SWOT Analysis
13.3.7 Merck KGaA
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.7.4 SWOT Analysis
13.3.8 Novartis AG
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.8.4 SWOT Analysis
13.3.9 Pfizer Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.9.4 SWOT Analysis
13.3.10 Sanofi S.A.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Scynexis Inc.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials